NewsAI-assisted

Nipro and Stevanato Group Team Up For D2F™ Vials With EZ-fill® Technology

Nipro PharmaPackaging launches D2F™ glass vials with EZ-fill® technology for efficient pharmaceutical use.

Simantini Singh Deo
By Simantini Singh Deo
Senior Content Writer
Oct 8, 2024Updated Jun 26, 2025 · 2 min read
Nipro and Stevanato Group Team Up For D2F™ Vials With EZ-fill® Technology
https://www.glassonline.com/nipro-d2f-glass-vials-powered-by-stevanatos-ez-fill-technology/
AI-assisted reporting
Reviewed by Simantini Singh Deo, Senior Content Writer

Nipro PharmaPackaging, a worldwide leader in glass tubing, primary packaging, and medical devices, has introduced its pioneering D2F™ (Direct-to-Fill) glass vials. Equipped with Stevanato Group’s state-of-the-art EZ-fill® technology, these vials provide a premium, ready-to-use (RTU) solution that aligns with the strict standards and evolving demands of the pharmaceutical industry.


Stephan Arnold, CEO Nipro PharmaPackaging, said in a statement, “We are excited to introduce D2F™ glass vials, offering a reliable and efficient RTU packaging solution that addresses the evolving needs of the pharmaceutical industry. These vials exemplify our mission to deliver trust with premium primary pharma packaging solutions.”


Mauro Stocchi, Chief Business Officer at Stevanato Group, also mentioned “The collaboration with Nipro represents another important milestone for Stevanato Group's EZ-fill® pre-sterilized platform. Nipro's adoption of the EZ-fill® platform further validates Stevanato Group's technological leadership and strengthens our market position in secondary packaging for aseptic manufacturing. The EZ-fill® platform is an increasingly reliable, scalable, and cost-effective solution and industry-validated technology, and we believe it will become a widely recognized standard in the industry."

TopicsNews
Simantini Singh Deo
Written by
Simantini Singh Deo
Senior Content Writer

Simantini Singh Deo works on the latest and trending news happening daily in the pharma world.

Discussion

Loading discussion…

More from Pharma News

All stories →